HF prevalence and evolution of HF in DM II patients at high risk

Trial Identifier: D1843R00313
Sponsor: AstraZeneca
NCTID:: NCT04482283
Start Date: July 2020
Primary Completion Date: November 2024
Study Completion Date: November 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Greece Athens, Greece, 12462
Greece Athens, Greece, 11527
Greece Athens, Greece, 11526
Greece Heraklion, Greece, 71500
Greece Larissa, Greece, 41110
Greece Patra, Greece, 26504
Greece Thessaloniki, Greece, 54636
Greece Thessaloniki, Greece, 54642
Greece, D1843R00313 Alexandroupolis, D1843R00313, Greece, 68100
Greece, D1843R00313 Athens, D1843R00313, Greece, 10676